Neuromelanin is an immune stimulator for dendritic cells in vitro

BMC Neuroscience

Volumn 12, Issue , 2011, Pages

  Oberländer, Uwe ^a   Pletinckx, Katrien ^a   Döhler, Anja ^a   Müller, Nora ^a   Lutz, Manfred B ^a   Arzberger, Thomas ^b   Riederer, Peter ^a   Gerlach, Manfred ^a   Koutsilieri, Eleni ^a   Scheller, Carsten ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; DOPAMINE MELANIN; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANIN; NEUROMELANIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHAGOCYTOSIS; PHENOTYPE; SUBSTANTIA NIGRA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 81055149780     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-12-116     Document Type: Article

References (43)

1. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001, 76(6):1766-1773. 10.1046/j.1471-4159.2001.00186.x, 11259494.
2. Fenichel GM, Bazelon M. Studies on neuromelanin. II. Melanin in the brainstems of infants and children. Neurology 1968, 18(8):817-820.
3. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005, 75(2):109-124. 10.1016/j.pneurobio.2005.02.001, 15784302.
4. Mann DM, Yates PO. Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 1974, 97(3):489-498.
5. Ishikawa A, Takahashi H. Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism. J Neurol 1998, 245(11 Suppl 3):P4-9.
6. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46(4):598-605. 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F, 10514096.
7. Depboylu C, Schafer MK, Arias-Carrion O, Oertel WH, Weihe E, Hoglinger GU. Possible involvement of complement factor c1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J Neuropathol Exp Neurol 2011, 70(2):125-132. 10.1097/NEN.0b013e31820805b9, 21343881.
8. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003, 26(11):578-580. 10.1016/j.tins.2003.08.009, 14585596.
9. Rao KS, Hegde ML, Anitha S, Musicco M, Zucca FA, Turro NJ, Zecca L. Amyloid beta and neuromelanin--toxic or protective molecules? The cellular context makes the difference. Prog Neurobiol 2006, 78(6):364-373. 10.1016/j.pneurobio.2006.03.004, 16682109.
10. Ben-Shachar D, Riederer P, Youdim MB. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 1991, 57(5):1609-1614. 10.1111/j.1471-4159.1991.tb06358.x, 1919577.
11. Double KL, Halliday GM, Henderson J, Griffiths FM, Heinemann T, Riederer P, Gerlach M. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp Neurol 2003, 184(1):530-535. 10.1016/j.expneurol.2003.08.006, 14637122.
12. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003, 17(3):500-502.
13. Zecca L, Wilms H, Geick S, Claasen JH, Brandenburg LO, Holzknecht C, Panizza ML, Zucca FA, Deuschl G, Sievers J, Lucius R. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol 2008, 116(1):47-55. 10.1007/s00401-008-0361-7, 18343932.
14. Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 2011, 19(1):63-72. 10.1007/s12640-009-9140-z, 19957214.
15. Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 2006, 70:133-142. 10.1007/978-3-211-45295-0_21, 17017520.
16. Double KL, Rowe DB, Carew-Jones FM, Hayes M, Chan DK, Blackie J, Corbett A, Joffe R, Fung VS, Morris J, Riederer P, Gerlach M, Halliday GM. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol 2009, 217(2):297-301. 10.1016/j.expneurol.2009.03.002, 19289120.
17. Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 2006, 12(11):521-528. 10.1016/j.molmed.2006.09.007, 17027339.
18. Riederer P, Foley P. Mini-review: multiple developmental forms of parkinsonism. The basis for further research as to the pathogenesis of parkinsonism. J Neural Transm 2002, 109(12):1469-1475. 10.1007/s007020200095, 12486487.
19. Benkler M, Agmon-Levin N, Shoenfeld Y. Parkinson's disease, autoimmunity, and olfaction. Int J Neurosci 2009, 119(12):2133-2143. 10.3109/00207450903178786, 19916845.
20. Moscavitch SD, Szyper-Kravitz M, Shoenfeld Y. Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system interrelationship. Clin Immunol 2009, 130(3):235-243. 10.1016/j.clim.2008.10.010, 19097945.
21. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, Papadimitriou A, Kalofoutis A, Buchman VL. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007, 101(3):749-756. 3154646, 17448146.
22. Roselli F, Russo I, Fraddosio A, Aniello MS, De Mari M, Lamberti P, Livrea P, Defazio G. Reversible Parkinsonian syndrome associated with anti-neuronal antibodies in acute EBV encephalitis: a case report. Parkinsonism Relat Disord 2006, 12(4):257-260. 10.1016/j.parkreldis.2005.11.004, 16459123.
23. Hassin-Baer S, Levy Y, Langevitz P, Nakar S, Ehrenfeld M. Anti-beta2-glycoprotein I in Sjogren's syndrome is associated with parkinsonism. Clin Rheumatol 2007, 26(5):743-747. 10.1007/s10067-006-0398-8, 17057945.
24. Wilhelm KR, Yanamandra K, Gruden MA, Zamotin V, Malisauskas M, Casaite V, Darinskas A, Forsgren L, Morozova-Roche LA. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. Eur J Neurol 2007, 14(3):327-334.
25. Dale RC, Church AJ, Surtees RA, Lees AJ, Adcock JE, Harding B, Neville BG, Giovannoni G. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004, 127(Pt 1):21-33.
26. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128(Pt 11):2665-2674.
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252. 10.1038/32588, 9521319.
28. McMenamin PG. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol 1999, 405(4):553-562. 10.1002/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6, 10098945.
29. Bailey TW, Hermes SM, Andresen MC, Aicher SA. Cranial visceral afferent pathways through the nucleus of the solitary tract to caudal ventrolateral medulla or paraventricular hypothalamus: target-specific synaptic reliability and convergence patterns. J Neurosci 2006, 26(46):11893-11902. 10.1523/JNEUROSCI.2044-06.2006, 17108163.
30. Zozulya AL, Ortler S, Lee J, Weidenfeller C, Sandor M, Wiendl H, Fabry Z. Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. J Neurosci 2009, 29(1):140-152. 10.1523/JNEUROSCI.2199-08.2009, 2942091, 19129392.
31. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 2001, 166(4):2717-2726.
32. Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P, Stern LJ, Strominger JL, Riese R. Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001, 98(11):6295-6300. 10.1073/pnas.111152498, 33462, 11371643.
33. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 2007, 8(2):172-180. 10.1038/ni1430, 17206145.
34. Zecca L, Costi P, Mecacci C, Ito S, Terreni M, Sonnino S. Interaction of human substantia nigra neuromelanin with lipids and peptides. J Neurochem 2000, 74(4):1758-1765.
35. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003, 9(12):1484-1490. 10.1038/nm960, 14625544.
36. Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity 2008, 41(2):123-132. 10.1080/08916930801929021, 18324481.
37. Coutant F, Perrin-Cocon L, Agaugue S, Delair T, Andre P, Lotteau V. Mature dendritic cell generation promoted by lysophosphatidylcholine. J Immunol 2002, 169(4):1688-1695.
38. Perrin-Cocon L, Coutant F, Agaugue S, Deforges S, Andre P, Lotteau V. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J Immunol 2001, 167(7):3785-3791.
39. Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T, Riederer P, Naoi M. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 2007, 114(12):1559-1567. 10.1007/s00702-007-0789-2, 17690948.
40. Li J, Scheller C, Koutsilieri E, Griffiths F, Beart PM, Mercer LD, Halliday G, Kettle E, Rowe D, Riederer P, Gerlach M, Rodriguez M, Double KL. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 2005, 95(2):599-608. 10.1111/j.1471-4159.2005.03404.x, 16135091.
41. Ostergren A, Svensson AL, Lindquist NG, Brittebo EB. Dopamine melanin-loaded PC12 cells: a model for studies on pigmented neurons. Pigment Cell Res 2005, 18(4):306-314. 10.1111/j.1600-0749.2005.00239.x, 16029423.
42. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223(1):77-92. 10.1016/S0022-1759(98)00204-X, 10037236.
43. Zal T, Volkmann A, Stockinger B. Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 1994, 180(6):2089-2099. 10.1084/jem.180.6.2089, 2191800, 7964486.